Search clinical trials for: Erythropoiesis Stimulating Agent

Total 188942 results

Assiut University

Not yet recruiting

Prevalence of Erythropoiesis Stimulating Agents Hyporesponsiveness in Dialysis Patients in Assiut University Hospital

Erythropoietin Resistant Anemia (EPO Resistant Anemia)
GlaxoSmithKline

Recruiting

Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P) (ASCEND-P)

Anaemia

United States, Italy, Spain, France, United Kingdom, Korea, Republic of, Netherlands, Japan, Argentina, Belgium, Turkey
Julia Xu
Carnegie Mellon University; American Society of Hematology

Recruiting

Hydroxyurea and EPO in Sickle Cell Disease (ACHiEvE-SCD)

Sickle Cell Disease | Anemia, Sickle Cell

United States, Nigeria
Kaohsiung Medical University Chung-Ho Memorial...
National Sun Yat-sen University

Recruiting

Use of a Novel Artificial Intelligence Assisted Platform to Assess Optimal Dosing and Treatment Strategy of Erythropoiesis-stimulating Agents (ESA) in Hemodialysis Patients (AI)

End Stage Renal Disease on Dialysis

Taiwan
Hospital Son Espases

Recruiting

Paricalcitol Improves Anemia of Inflammation (PIERAID)

Anemia

Spain
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Anaemia

United States, Australia, Korea, Republic of, Spain, Taiwan, Bulgaria, Canada, Italy, Russian Federation, Ukraine, Argentina, Belgium, France, Philippines, South Africa, Thailand, Israel, Sweden, Singapore, Czechia, Hong Kong, Net... and more
Cambridge University Hospitals NHS Foundation Trust
GlaxoSmithKline

Completed

Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease. (OPERA-CKD)

Cardiovascular Diseases | Chronic Kidney Disease

United Kingdom
Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (CONVERSION)

Anemia of Chronic Kidney Disease

United States
Helwan University

Completed

Erythropoiesis Stimulating Agents for Anemia Management in Egyptian Hemodialysis Patients

Anemia of Chronic Kidney Disease | Chronic Renal Failure | Chronic Renal Failure Anemia

Egypt
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland
University of Louisville
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease

Anemia of End Stage Renal Disease

United States
FibroGen
AstraZeneca

Completed

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Anemia Associated With End Stage Renal Disease (ESRD)

United States
Centre Hospitalier Annecy Genevois

Completed

Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis (Ruxo-EPO)

Myelofibrosis; Anemia
Rennes University Hospital

Completed

Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections (SELFEPO)

Renal Insufficiency, Chronic | Organ Graft

France
GlaxoSmithKline

Completed

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Anaemia | Aspergillosis, Allergic Bronchopulmonary

Australia, Korea, Republic of, Spain, United States, Taiwan, Bulgaria, Mexico, Ukraine, Argentina, Belgium, South Africa, Singapore, Austria, Canada, Netherlands, Russian Federation, Sweden, Turkey, United Kingdom, Germany, Romania and more
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
FibroGen
Astellas Pharma Inc

Completed

Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment

Anemia | Dialysis

Hong Kong, United States, Singapore, Russian Federation
Kaohsiung Medical University Chung-Ho Memorial...

Completed

A Model of Computer-assisted Prescription of Erythropoiesis-stimulating Agents (ESA) in Patients Under Hemodialysis

End Stage Renal Disease

Taiwan
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Translational Research Center for Medical Innovation...
Niigata University

Completed

Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents (BRIGHTEN)

Chronic Kidney Disease | Renal Anemia

Japan
GlaxoSmithKline

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

Anaemia

Spain, United States, Russian Federation, Canada, Germany
Vifor Fresenius Medical Care Renal Pharma
Worldwide Clinical Trials; Fresenius Medical Care Deutschland GmbH

Terminated

Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial (ANEMEX)

Anemia | End Stage Renal Disease

United Kingdom
Astellas Pharma a/s

Completed

A Non-interventional, Epidemiological, Registry-based Evaluation of Anaemia in Swedish Patients With Chronic Kidney Disease (ASK)

Chronic Kidney Disease Associated Anemia

Sweden
GlaxoSmithKline

Completed

Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents

Anaemia

Japan
The George Institute
National Health and Medical Research Council, Australia; Baxter Healthcare...

Completed

A Clinical Trial of IntensiVE Dialysis (ACTIVE)

End Stage Renal Disease | Renal Replacement Therapy | End Stage Kidney Disease | Renal Dialysis | Uremia

New Zealand, Canada, Australia, China
Andrea L Woodland

Completed

Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients

Anemia | Chronic Kidney Disease
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
GlaxoSmithKline

Completed

Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis

Anaemia

United States
Takeda

Completed

Efficacy and Safety of Peginesatide (AF37702) in the Treatment of Anemia in Participants With Chronic Kidney Disease

Anemia | Chronic Kidney Disease | Pure Red Cell Aplasia | Chronic Renal Failure

United Kingdom, France, Germany
Chinese University of Hong Kong

Completed

Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease

Anemia of Chronic Kidney Disease

Hong Kong
Amgen

Completed

A Novel Erythropoiesis Stimulating Protein (NESP; Darbopoetin Alfa) for the Treatment of Anemia in Lung Cancer Patients Receiving Multi-cycle Platinum-Containing Chemotherapy

Anemia
Akebia Therapeutics

Withdrawn

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
GlaxoSmithKline

Completed

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

Anaemia

United States, Australia, Canada, Hungary, Spain, Sweden, Czechia, Germany, United Kingdom, Korea, Republic of, Russian Federation, France, Denmark, Poland, Japan
Association pour la recherche sur les Affections...

Completed

Biological Predictive Factors of Response to ESA in Low Risk MDS Patients

Myelodysplastic Syndromes
GlaxoSmithKline

Completed

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

Anaemia

United States
GlaxoSmithKline

Completed

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Anaemia

United States, Australia, Korea, Republic of, Canada, Czechia, Norway, Spain, United Kingdom, Russian Federation, Germany, Sweden, Denmark, Poland, France, Hungary, Japan
Translational Research Center for Medical Innovation...
Showa University School of Medicine

Completed

PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease (PREDICT)

Diabetes | Chronic Kidney Disease

Japan
Janssen Research & Development, LLC

Completed

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Breast Cancer | Neoplasm Metastasis

United States, Poland, Ukraine, Taiwan, Argentina, Colombia, Mexico, Bulgaria, India, Malaysia, Romania, Russian Federation, South Africa, Hong Kong, Chile, Brazil, Philippines, Ecuador, Macedonia, The Former Yugoslav Republic... and more
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease

Anaemia

Japan
GlaxoSmithKline
PPD

Completed

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Anaemia

United States, Germany, Canada, Sweden, Denmark, Norway
GlaxoSmithKline

Terminated

Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia

Anemia

United States
Peking University

Unknown

Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation

Lymphoma | Anemia | Hematopoietic Stem Cell Transplantation

China
Hoffmann-La Roche

Terminated

A Study of Subcutaneous Mircera, Versus no Erythropoiesis-Stimulating Agent (ESA) Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant

Anemia

France, United Kingdom, Germany, Spain, Belgium, Italy

3

Subscribe